Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2G5
UPID:
OFUT2_HUMAN
Alternative names:
Peptide-O-fucosyltransferase 2
Alternative UPACC:
Q9Y2G5; Q6PJV1; Q7Z4N0; Q8WWU6; Q9BQS4; Q9BQS5; Q9UFY3
Background:
GDP-fucose protein O-fucosyltransferase 2, also known as Peptide-O-fucosyltransferase 2, plays a crucial role in protein modification. It catalyzes the attachment of fucose to serine or threonine residues in specific protein sequences, impacting various protein families including ADAMTS and thrombospondin. This enzymatic activity is essential for proper protein secretion and has implications in cellular processes such as epithelial to mesenchymal transition.
Therapeutic significance:
Understanding the role of GDP-fucose protein O-fucosyltransferase 2 could open doors to potential therapeutic strategies. Its involvement in critical protein modification pathways suggests a foundational role in cellular function and disease modulation.